Author Archives: Yedida Y Bogachkov PhD

Gene Therapy for CLN2, LX1004, Supported by $100M in Financing

Lexeo Therapeutics announced that it raised $100 million in a financing round to help support the development of pipeline therapies, including LX1004, a potential gene therapy for CLN2 disease, also known as late infantile Batten disease. Other potential treatments supported through this Series B financing include LX2006, a gene therapy for…